Dosing and Safety

Studied human doses are described as escalating from 500 mg to 1 g, with 2 g showing exposure similar to 1 g. A roughly one-day half-life is used to support once-daily dosing in studied protocols. Alternate-day dosing is discussed as plausible, but not established by human clinical evidence. Drug-interaction concerns are described as low in older adults taking multiple medications, with no major interaction concerns reported. Powders, soft gels, and protein-containing formats are said to have similar bioavailability. Available evidence is presented as showing similar absorption across tested forms and meal conditions. Long-term lifelong safety and use in all populations remain incompletely established. The source reports no observed side effects in trials spanning participants aged 19 to 89.